Navigation Links
CHI Joins More Than 30 State Life Sciences Associations in Urging Budget Conferees to Fix FDA User Fee Sequester
Date:11/18/2013

LA JOLLA, Calif. (PRWEB) November 18, 2013

Today, a coalition of more than 30 state and regional life sciences associations, including the California Healthcare Institute (CHI), sent House and Senate Budget Conferees a letter urging swift action to exempt U.S. Food and Drug Administration (FDA) user fees from sequestration.

Last year, passage of the FDA Safety and Innovation Act (FDASIA) renewed FDA’s authority to collect user fees and provided much needed improvements to regulatory review processes. In fact, industry agreed to pay increased user fees in order to facilitate the needed system and process improvements under the renewed FDA user fee law. Since its inception for drugs in 1992 and for devices in 2002, the user fee program at the FDA has increasingly relied on industry-paid user fees to supplement congressional appropriations for its product review activities. Under FDASIA, user fees now fund approximately 60-65 percent of the cost of FDA human drug and biologics review activities, and approximately one-third of the cost of FDA device and diagnostics review activities.

According to the Office on Management and Budget and U.S. Department of Treasury, sequestration has reduced FDA’s budget authority for user fees by $85 million in FY2013.

“Ending the sequestration of user fees is a top priority of CHI,” said Todd Gillenwater, senior vice president of public policy for CHI, the public policy association representing California’s statewide life sciences sector. “This letter, signed by more than two dozen state and regional life science associations, demonstrates the significant nationwide concern about the impact of user fee sequestration on FDA’s ability to carry out its critically important mission to bring safe and effective new drugs, biologics, devices and diagnostics to patients.”

FDA leaders have expressed concerns that the sequestration of user fees puts at risk key commitments negotiated under last year’s renewal of the user fee programs through FDASIA, and may result in delays in the availability of novel and important new drugs and devices for patients. The Center for Drug Evaluation and Research Director Janet Woodcock, M.D., and Center for Devices and Radiological Health Director Jeff Shuren, M.D., J.D. echoed these concerns at Friday’s House Energy & Commerce Subcommittee on Health hearing on the agency’s progress in implementing FDASIA.

In July, Rep. Anna G. Eshoo (D-Palo Alto) together with a bipartisan collection of California members, including Reps. Tony Cárdenas (D-San Fernando Valley), Sam Farr (D-San Francisco), Doris Matsui (D-Sacramento), Scott Peters (D-San Diego), David G. Valadao (R-Hanford) and Henry A. Waxman (D-Santa Monica), introduced legislation that would eliminate future sequestration of industry-paid user fees. In order to make the legislation budget-neutral, the bill – H.R. 2725, the FDA Safety Over Sequestration, or FDA SOS Act – does not address the user fees already sequestered in FY2013 or FY2014. H.R. 2725 currently has 68 cosponsors, including 24 members of the California congressional delegation.

“User fees are private monies – not federal taxpayer dollars,” said Gillenwater. “We hope the budget conferees take into consideration this multi-state life science association letter, along with the growing number of bipartisan cosponsors of H.R. 2725, and adopt this no-cost, common sense fix as part of any upcoming budget agreement.”

About CHI:
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11344346.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Craig Peloquin Joins Glissandra Skin Care as VP of Sales and Marketing
2. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
3. Dr. Ungerleider Joins Forces with Childhelp
4. ReachMD Radio Joins Clear Channel’s iHeartRadio
5. Soltex Consulting Joins Medidata Partner Program to Better Optimize Clinical Processes
6. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
7. Green Dot Holdings LLC CEO, Mark Remmert, Joins Industry Thought Leaders to Discuss Holistic Sustainable Design at A Better World by Design Conference
8. Robert Tungatt, Regulatory Compliance and Cold Chain Excellence Specialist Joins QuickSTAT
9. Chinese Leader in Genomics Joins Science Center's Port Community
10. Greg Plum Joins the SoundConnect Team
11. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® ... adults at home or in healthcare facilities during periods of rest. A lightweight, ...
(Date:2/23/2017)... Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies ... Marbán, Ph.D, president and chief executive officer, is scheduled to ... Cowen and Company 37th Annual Health Care Conference Tuesday, March ... 29th Annual ROTH Conference Tuesday, ... Dana Point, CA ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
Breaking Biology Technology:
(Date:1/24/2017)... NEW YORK , Jan. 24, 2017 /PRNewswire/ ... market study of the laboratory use of nuclear ... of 363 experienced end-users and profiled current practices, ... three years, as well as growth and opportunities. ... NMR, Instrument suppliers, NMR instruments, needs and innovation ...
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):